Tag - pharmaceuticals

 
Menu
Search
 
August 23, 2025
 

Today's print edition

Home Delivery
Subscribe for more access

PHARMACEUTICALS

Japan Times
BUSINESS
Jul 3, 2020
How Moderna execs are cashing in during the race to develop COVID-19 vaccine
Biotech firm Moderna Inc. could reap tens of billions of dollars in sales and stock appreciation if it wins the race for a COVID-19 vaccine. If it loses, the early-stage company’s value could crash.
Japan Times
ASIA PACIFIC / Science & Health
Jul 2, 2020
How China's CanSino Biologics jumped to the front of the coronavirus vaccine race
The firm has boosted its scientific prowess by tying up with the Canadian government's largest research organization, maintaining links despite geopolitical rows.
JAPAN / Science & Health
Jun 24, 2020
Wanted: More COVID-19 patients in Japan ... for clinical trials
Japan has become a victim of its own success as slowing new infections have led to a shortage of patients to enroll in trials for treatments and vaccines.
Japan Times
BUSINESS / Companies
Jun 23, 2020
Gilead targets remdesivir supply for 2 million COVID-19 patients by year-end
The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, which is currently administered only intravenously.
BUSINESS / Companies
Jun 22, 2020
Japan drugmaker to tie up with universities to develop new test method for coronavirus
Japanese pharmaceutical company Shionogi & Co. said Monday that it will collaborate with universities in the country to put into practical use a new testing method for the novel coronavirus.
Japan Times
BUSINESS / Markets
Jun 8, 2020
Chugai stock surges 60% to rival Sony's value on hopes for virus treatment
Chugai Pharmaceutical is now Japan's biggest drug company by market value after overtaking Daiichi Sankyo and Takeda Pharmaceutical.
Japan Times
WORLD / Science & Health
Jun 2, 2020
Scientists hunt pandemic hot spots in race to test vaccines
The first wave of the COVID-19 pandemic may be waning. For vaccine developers, that could be a problem.
Japan Times
WORLD / Science & Health
Jun 1, 2020
After fast-tracking Japanese COVID-19 drug, Russia to roll out 'game changer' next week
Russia will start administering its first approved antiviral drug to treat coronavirus patients next week, its state financial backer told Reuters, a move it described as "a game changer" that should speed a return to normal economic life.
Japan Times
BUSINESS / Markets
May 26, 2020
Japan’s AnGes continues surge as coronavirus vaccine candidate moves closer to human trials
The progress of its drug development has led to wild swings in the stock, with shares falling more than 50 percent in two trading sessions earlier this month.
Japan Times
WORLD / Science & Health
May 23, 2020
Gilead’s remdesivir mainly helped healthier COVID-19 patients
Gilead Sciences Inc.’s remdesivir, the first medicine cleared for the treatment of COVID-19, mainly benefited healthier patients who weren’t dependent on ventilators or heart-lung bypass machines, according to published results of the study used to get the medicine on the market.
Japan Times
BUSINESS
May 21, 2020
No pause in coronavirus trial for Avigan, Japan's lead researcher says
The lead researcher in the coronavirus trial for flu drug Avigan says it’s too early to make a call on whether it works and shrugged off negative reports about the interim results, saying patients are still being enrolled.
Japan Times
COMMENTARY / World
May 19, 2020
Vaccine developers need to take their time
Positive study results have arrived quickly, but the next steps will be slower.
Japan Times
WORLD
May 19, 2020
Trump says he’s taking anti-malaria drug that led to FDA warning
Trump is a self-admitted germophobe, telling reporters he was wary of shaking hands even before the coronavirus pandemic.
Japan Times
WORLD / Science & Health
May 14, 2020
France says ‘unacceptable’ for U.S. to get Sanofi vaccine first
Giving the U.S. priority access to a Sanofi vaccine against the new coronavirus would be "unacceptable,” a French government minister said.
Japan Times
ASIA PACIFIC / Science & Health
May 13, 2020
A tale of two Japanese drugs in tests to fight COVID-19
Avigan and camostat are undergoing trials as they may be effective in treating illnesses brought on by coronavirus.
Japan Times
JAPAN / FOCUS
May 12, 2020
Abe follows Trump's example, approving drugs quickly after criticism
Japanese regulators are usually known for taking a year to approve new drugs, but authorized remdesivir just three days after receiving the application.
Japan Times
WORLD / Science & Health
May 2, 2020
U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir
Gilead Science Inc.'s antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in more hospitals around the United States.
Japan Times
WORLD / Science & Health
May 1, 2020
Virus drugmaker caught between making a profit and treating the world
Gilead Sciences Inc. may spend $1 billion on its breakthrough new treatment for COVID-19 this year alone, Chief Executive Officer Daniel O’Day said. How much revenue — if any — the company expects to generate is another matter.
Japan Times
WORLD / Science & Health
Apr 26, 2020
Countries and companies risk billions in race for coronavirus vaccine
Governments, charities and Big Pharma firms are making huge bets with extraordinarily low odds of success.
Japan Times
WORLD
Apr 23, 2020
Official says he was ousted for urging caution on Trump-touted virus drug
The ousted director of a key U.S. agency charged with developing drugs to fight the COVID-19 pandemic said Wednesday he was dismissed because he called for careful vetting of a treatment frequently touted by President Donald Trump.
Japan to revise romanization rules for first time in 70 years
The Agency for Cultural Affairs is recommending replacing the government’s long-standing Kunrei system with more widely used Hepburn-style spellings.
JR East cancels luxury train run over crew's boozing
East Japan Railway said Thursday that it will cancel one trip of a luxury overnight sleeper service, which was originally scheduled to depart from Ueno Station in Tokyo on Aug. 30, after crew members were found to have been drinking alcohol on duty.
Demystifying the manufacturing success of China
China’s massive scale, strong education system and competitive local governance have enabled it to reach the technological frontier and dominate high-tech manufacturing despite its low per capita gross domestic product.
Infectious diseases to watch for in Japan this summer amid surge of cases
An illustration of a colony of the Bordetella pertussis bacterium that causes pertussis, or whooping cough. As of Aug. 10, there were 64,467 cases reported this year, according to the latest data from the Japan Institute for Health Security.
103-year-old remembers Soviet attack right after WWII
Shoichi Takahashi holds a photo of himself when he was younger, in Otaru, Hokkaido, on May 17.
Alicia Keys closed Summer Sonic, but J-pop owned it
Summer Sonic’s 2025 lineup demonstrated its strength, showcasing the latest in J-pop, including “new kawaii” act Fruits Zipper.
Big burgers and bigger ambitions for Japan's Burger King
Kazuhiro Nomura, president of BK Japan Holdings, which operates Burger King in Japan
Tokyo crowned No.1 'workation' spot
Workations were a burgeoning trend in the corporate world for years before the COVID-19 pandemic turbocharged it.
Atsushi Kitagawara’s exhibition finds poetry in architecture
The inverted cone, one of Atsushi Kitagawara’s six signature elements in architecture, is a key feature of the Nakamura Keith Haring Collection museum building.
Candidates preparing to make final pitches for Sawamura Award
Hawks pitcher Livan Moinelo has a 1.13 ERA in 19 starts this season.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo’s Shinjuku Ward.
Kabukicho: Tokyo’s ‘stadium of desire’

Longform

Tetsuzo Shiraishi, speaking at The Center of the Tokyo Raids and War Damage, uses a thermos to explain how he experienced the U.S. firebombing of March 1945, when he was just 7 years old.
From ashes to high-rises: A survivor’s account of Tokyo’s postwar past
By Alex K.T. Martin

SUSTAINABLE JAPAN

Looking ahead to Yokohama’s Green × Expo 2027
Looking ahead to Yokohama’s Green × Expo 2027

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER